| Vol. 13.01 – 15 January, 2021 |
| |
|
|
| Scientists showed that systemic delivery of nanoparticle-formulated 1 methylpseudouridine-modified messenger RNA coding for disease-related autoantigens results in antigen presentation on splenic CD11c+ antigen-presenting cells in the absence of costimulatory signals. [Science] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors demonstrated that functional innate lymphoid cells cells could arise in the embryonic thymus from shared T cell precursors, preceding the emergence of CD4+CD8+ T cells. [Nature Immunology] |
|
|
|
| Researchers showed that deficiency in NF-κB-inducing kinase impaired glycolysis induction, rendering CD8+ effector T cells hypofunctional in the tumor microenvironment. [Nature Immunology] |
|
|
|
| During synovial tissue homeostasis, both monocyte-derived F4/80int and self-renewing F4/80hi tissue–resident, macrophage populations were identified. [Science Advances] |
|
|
|
| RNA sequencing of murine PDAC liver metastasis-infiltrated neutrophils show that P2RX1-deficient neutrophils express increased levels of immunosuppressive molecules, including PD-L1, and have enhanced mitochondrial metabolism. [Nature Communications] |
|
|
|
| Researchers showed that high-fat diet feeding greatly suppressed the expression of disulfide-bond A oxidoreductase-like protein (DsbA-L), a mitochondria-localized chaperone protein, in adipose-resident T cells, which correlated with reduced T cell mitochondrial function. [Nature Communications] |
|
|
|
| E7386 demonstrated clear antitumor activity via modulation of the Wnt/β-catenin signal pathway and alteration of the tumor and immune microenvironments, and its antitumor activity could be enhanced in combination with anti-PD-1 antibody. [Cancer Research] |
|
|
|
| Investigators characterized a spontaneous mutant mouse strain endowed with a hypomorphic Tyr129His variant of CD25, the α-chain of IL-2R, which resulted in diminished receptor expression and reduced IL-2R signaling. [Cellular & Molecular Immunology] |
|
|
|
| Scientists discovered that Tlr7-deficient nonobese diabetic (NOD) mice, a model of human type 1 diabetes, exhibited a significantly delayed onset and reduced incidence of type 1 diabetes compared with Tlr7-sufficient NOD mice. Mechanistic investigations showed that Tlr7 deficiency significantly altered B-cell differentiation and immunoglobulin production. [Cellular & Molecular Immunology] |
|
|
|
| The authors identified a role for the histone H3K79 methyltransferase DOT1L in controlling B‐cell differentiation. Mouse B cells lacking Dot1L failed to establish germinal centers and normal humoral immune responses in vivo. [EMBO Reports] |
|
|
|
| Researchers enumerated the intestinal lymph innate lymphoid cells (ILCs) that traffic from the intestine to the mesenteric lymph nodes. They provide a detailed characterisation of these lymph-migratory ILCs. [Mucosal Immunology] |
|
|
|
| Scientists found that CCR2highCX3CR1low monocytes recruited to the injured brain were cytokine-dependently converted into CCR2lowCX3CR1high macrophages, especially under the influence of IL-4 and IL-13, thereby attenuating the neuroinflammation following sterile ischemic stroke. [Translational Stroke Research] |
|
|
|
| Although immunization with T-dependent antigens increased B-cell receptor signaling, it led to plasma cells reduction and increased apoptosis. Dependent on the antigen, the early germinal centre B cell response was equally reduced and apoptosis increased. [iScience] |
|
|
|
|
| Using the structure provided by the well-described cancer–immunity cycle, scientists outline the key steps required for a successful antitumor immune response in the context of renal cell carcinoma, and describe the development of promising new immunotherapies within the context of this framework. [Nature Reviews Clinical Oncology] |
|
|
|
| The author discusses the evidence that the thymus serves as a unique lymphoid organ able to instruct T cells to recognize and be tolerant to harmless self before adopting the capacity to defend the body against potentially injurious non-self-antigens presented in the context of different challenges from infections to exposure to malignant cells. [Seminars in Immunopathology] |
|
|
|
|
| Boehringer Ingelheim and Enara Bio, announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform. [Boehringer Ingelheim (BusinessWire, Inc.)] |
|
|
|
|
|
|
|
| The Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| University of Florida – Gainesville, Florida, United States |
|
|
|
| Salk Institute of Biological Studies – La Jolla, California, United States |
|
|
|
| Salk Institute of Biological Studies – La Jolla, California, United States |
|
|
|
| Systimmune, Inc. – Redmond, Washington, United States |
|
|
|
|